MannKind is only beginning to explore the opportunities associated with the ability to deliver a peptide hormone in ways that mimic normal hormone physiology. The data from MannKind's pivotal Phase 3 trials of Technosphere(R) Insulin will start to become available in the third quarter of 2008. In the meantime, in a Phase 1 trial of MKC253, another Technosphere(R)-based product, blood levels of GLP-1 were observed to peak within three minutes of administration, which may mimic the natural short pulse of GLP-1 that is produced in a healthy individual in response to glucose ingestion. Following administration of MKC253, study subjects experienced a dose-dependent increase in insulin levels and a decrease in glucose levels. Even at the highest doses of MKC253, subjects did not report any sweating, nausea or vomiting whereas those side effects are associated with the use of injectable GLP-1 products that do not mimic the natural, pulsatile feature of this hormone. These data will be presented in detail at the upcoming meeting of the American Diabetes Association.
MannKind believes that a significant need exists for products that
offer efficacy and safety advantages in the delivery of peptide hormones.
MannKind is committed to continuing the clinical development of
Technosphere(R) Insulin and MKC253. A third peptide hormone for the
treatment of obesity is in preclinical development. Currently, MannKind has
sufficient financial resources to fund these programs and others through
the end of 2009. It is MannKind's intention to bring these treatments to
patients in collaboration with a leading pharmaceutical partner who shares
a commitment to im
|SOURCE MannKind Corporation|
Copyright©2008 PR Newswire.
All rights reserved